Ovarian Cancer

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Latest News

Avutometinib Plus Defactinib Generates Responses in Recurrent Low-Grade Serous Ovarian Cancer
Avutometinib Plus Defactinib Generates Responses in Recurrent Low-Grade Serous Ovarian Cancer

January 25th 2023

The combination of avutometinib and defactinib elicited responses in patients with recurrent low-grade serious ovarian cancer, according to data from a planned interim analysis of the registration-directed phase 2 RAMP-201 trial.

Genetic Analysis Helps Maximize Clinical Benefit with PARP Inhibitors in BRCA+ Ovarian Cancer
Genetic Analysis Helps Maximize Clinical Benefit with PARP Inhibitors in BRCA+ Ovarian Cancer

January 17th 2023

Targeting FRα Enters a New Era in Ovarian Cancer and Beyond
Targeting FRα Enters a New Era in Ovarian Cancer and Beyond

January 16th 2023

COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer
COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer

January 12th 2023

Luveltamab Tazevibulin Shows Encouraging Activity in Frα-Selected Advanced Ovarian Cancer
Luveltamab Tazevibulin Shows Encouraging Activity in Frα-Selected Advanced Ovarian Cancer

January 11th 2023

Video Series
Video Interviews
Podcasts

More News